RXO Inc SEC Filings

RXO, Inc. reported that one of its directors received a grant of restricted stock units on January 2, 2026. The grant covers 14,517 restricted stock units (RSUs), each representing a contingent right to receive either one share of RXO common stock or a cash payment equal to the fair market value of one share upon settlement.

The RSUs are scheduled to vest in full on January 2, 2027, subject to the director’s continued service on the board and a deferral election. Following this transaction, the director beneficially owns 148,522 derivative securities, including RSUs tied to 7,745 shares of common stock that vested on January 2, 2026 but are subject to a deferral election, with delivery of shares to follow the applicable deferral terms.

RXO, Inc. reported that one of its directors completed several equity transactions on January 2, 2026. The director acquired 7,745 shares of common stock at a stated price of $0 through the exercise of derivative awards and, after this transaction, directly held 283,161 common shares.

On the same date, the director was granted 14,517 restricted stock units (RSUs), each representing a right to receive either one share of common stock or a cash amount equal to its fair market value. These RSUs are scheduled to vest in full on January 2, 2027, subject to continued service as a director. A prior RSU award covering 7,745 units vested on January 2, 2026, resulting in the corresponding common shares being issued.

RXO, Inc. reported an insider equity transaction by one of its directors on 01/02/2026. The director acquired 7,745 shares of common stock at a price of $0 through the conversion of previously granted restricted stock units (transaction code M), bringing direct ownership to 34,275 common shares.

On the same date, the director received a new award of 14,517 restricted stock units (RSUs), each representing the right to receive either one share of common stock or a cash payment equal to its fair market value upon settlement. These RSUs are scheduled to vest in full on January 2, 2027, provided the director continues to serve on the board. Previously granted RSUs vested on January 2, 2026, triggering the share acquisition.

RXO, Inc. (RXO) director reported an open-market purchase of company stock. On 11/20/2025, the reporting person bought 8,317 shares of RXO common stock in a transaction coded "P" (purchase), at a weighted average price of $10.61 per share, within a price range of $10.45 to $10.75.

Following this transaction, the director beneficially owns 275,416 shares of RXO common stock directly. The filing notes that detailed trade data by price level is available upon request.

RXO, Inc. director reported an open-market purchase of 9,350 shares of common stock on 11/17/2025 at a weighted average price of $10.75, bringing direct ownership to 91,137 shares.

The filing also shows beneficial ownership of restricted stock units (RSUs), including 7,745 RSUs that vest in full on January 2, 2026, and 126,260 RSUs that have vested and are subject to a deferral election. Each RSU represents the right to receive either one share of RXO common stock or a cash amount equal to its fair market value upon settlement.

The amendment was made solely to voluntarily include the director’s beneficial ownership of RSUs reported in Table II.

RXO, Inc. reported an insider share purchase by a company director. On 11/17/2025, the reporting person bought 9,350 shares of RXO common stock in the open market, coded as a purchase transaction.

The weighted average purchase price was $10.75 per share, with individual trades ranging from $10.74 to $10.76. Following this transaction, the director directly beneficially owns 91,137 shares of RXO common stock.

RXO, Inc. (RXO) reported an insider equity transaction by its Chief Executive Officer and Director. On 11/14/2025, 1,565 Restricted Stock Units (RSUs) were converted into an equal number of shares of common stock at an exercise price of $0, reflecting scheduled vesting of a prior equity award. To cover related tax obligations, 684 shares of common stock were withheld by the company at a price of $10.86 per share, with no open market sales by the reporting person.

After these transactions, the reporting person directly owned 4,731 shares of RXO common stock and also had indirect holdings of 7,775 shares held by a trust and 271,767 shares held through a controlled limited liability company. The reporting person also beneficially owned 605,967 derivative securities in the form of RSUs, including 74,932 RSUs previously reported, which each represent the right to receive one share of common stock or an equivalent cash amount upon settlement under the award’s vesting schedule.

RXO, Inc. — Schedule 13G/A ownership update. Orbis Investment Management Limited and related advisers reported beneficial ownership of RXO common stock, reflecting a significant passive stake as of the event date 09/30/2025.

The filing lists an aggregate 32,573,158 shares beneficially owned, representing 19.9% of the class. Within this total, Orbis Investment Management Limited has sole voting and dispositive power over 31,581,774 shares; Orbis Investment Management (U.S.), L.P. has 963,408 shares; and Allan Gray Australia Pty Ltd has 27,976 shares. The reporting persons certify the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.

RXO, Inc. reported an insider transaction on a Form 4: the Chief Accounting Officer sold 33,343 shares of common stock on 11/10/2025 (transaction code S) at a weighted average price of $11.57, with individual sale prices ranging from $11.51 to $11.68. Following the sale, the reporting person directly owned 43,558 shares.